Cue Biopharma
CUE
63 hedge funds and large institutions have $43M invested in Cue Biopharma in 2023 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 9 closing their positions.
101% more call options, than puts
Call options by funds: $207K | Put options by funds: $103K
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
23% more capital invested
Capital invested by funds: $35.1M → $43M (+$7.97M)
5% more funds holding
Funds holding: 60 → 63 (+3)
0.02% less ownership
Funds ownership: 0.95% → 0.93% (-0.02%)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$435K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$421K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$396K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$285K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PM
Prosight Management
Dallas,
Texas
|
-$2.19M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$366K |
| 3 |
CC
Carlson Capital
Dallas,
Texas
|
-$353K |
| 4 |
BL
Bleichroeder LP
New York
|
-$338K |
| 5 |
Renaissance Technologies
New York
|
-$288K |
CUE Hedge Fund Activity: Q1 2023 in Review
63 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2023, worth a combined $43M — up 23% from $35.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new CUE positions and 9 closed out — a net gain of 3 holders — while 12 added to existing stakes and 17 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $435K. The largest seller was Prosight Management, cutting an estimated $2.19M.
- 63 institutional investors held Cue Biopharma (CUE) as of Q1 2023, up from 60 in Q4 2022.
- Funds reported $43M of Cue Biopharma stock for Q1 2023, up 23% quarter-over-quarter.
- 12 funds opened new Cue Biopharma positions in Q1 2023 and 9 closed out, a net change of +3 holders.
- The largest Cue Biopharma buyer in Q1 2023 was Geode Capital Management, an estimated $435K added.
- The largest Cue Biopharma seller in Q1 2023 was Prosight Management, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2023.